Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Compass Therapeutics, Inc. Director's Dealing 2025

Apr 8, 2025

32588_dirs_2025-04-08_de3e7aca-a71f-48ee-9117-a6160028a9a3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2025-04-07

Reporting Person: Anderman Jonathan (Gen Counsel & Corporate Sec)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-04-07 Common Stock P 20000 $1.54 Acquired 21000 Direct